News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellerant Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of CLT-008 for Chemotherapy Induced Neutropenia in Acute Leukemia Patients


3/22/2011 8:22:37 AM

SAN CARLOS, Calif.--(BUSINESS WIRE)--Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia. CLT-008, a first-in-class, allogeneic cell-based therapy, is under development to provide hematopoietic support following high-dose chemotherapy or radiation exposure, by shortening the time to neutrophil recovery and decreasing the risks of febrile neutropenia and infection.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES